ReviewJournal of addiction medicine
Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review.
Review in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review.Journal of substance abuse treatment · 2022Pooled it
- Evidence Base on Outpatient Behavioral Treatments for Adolescent Substance Use, Update 2018-2023: Current Status, Best Practices, and Opportunities for Advancing the Science.Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53Pooled it
- Extended-release naltrexone for youth with opioid use disorder.Journal of substance abuse treatment · 2021Trial
- Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial.The American journal on addictions · 2021Trial
- Inpatient initiation of long-acting injectable buprenorphine for adolescents and young adults with opioid use disorder.Journal of substance use and addiction treatment · 2026Article
- Adolescent Substance Use Screening in the Emergency Department.Journal of the American College of Emergency Physicians open · 2026Review
- Review
- Medication and Acute Care Use in Young Adults With Opioid Use Subject to Medicaid Prescription Caps.JAMA health forum · 2026Article
- Article
- Impact Of Relationship Quality and Recovery Attitudes on Medication for Opioid Use Disorder Among Young Adults.Journal of drug issues · 2025Article
- Engagement, initiation, and retention in medication treatment for opioid use disorder among young adults: A narrative review of challenges and opportunities.Journal of substance use and addiction treatment · 2024Review
- Emergency department management of opioid use disorder in pediatric patients.Journal of the American College of Emergency Physicians open · 2024Article
- Clinician Willingness to Prescribe Medications for Opioid Use Disorder to Adolescents in Indiana.JAMA network open · 2024Article
- Patient and provider medication preferences affect treatment outcomes among adolescents and young adults with opioid use disorder.Journal of substance use and addiction treatment · 2024Article
- Article
- Implementation of Substance Use Services to Justice-Involved Youth: Examining Barriers, Facilitators, and Best Practices.Journal of correctional health care : the official journal of the National Commission on Correctional Health Care · 2023Review
- National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018.Substance abuse · 2023Observational
- Substance use severity as a predictor for receiving medication for opioid use disorder among adolescents: An analysis of the 2019 TEDS.Drug and alcohol dependence · 2023Article
- Buprenorphine Dispensing Among Youth Aged ≤19 Years in the United States: 2015-2020.Pediatrics · 2023Article
- Launching Relationship-Oriented Behavioral Services for Youth Opioid Use Disorder: Innovations in Medication Decision-Making and Adherence Planning.Child & family behavior therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
: In the past decade, a new cohort of adolescents and young adults with opioid use disorders (OUD) has emerged. While medications and psychosocial treatments are available, few adolescents and young adults with OUD can access and remain in treatment. Effective, practical, and scalable treatment paradigms for this young population are needed. Buprenorphine is a medication with unique pharmacological and regulatory characteristics that make it a promising component of adolescent and young adult OUD treatment models. Three randomized controlled trials and multiple observational studies have evaluated the use of buprenorphine to treat this population. However, data from these studies have not been consolidated into an up-to-date summary that may be useful to clinicians. The objective of this narrative review is to inform clinical practice by summarizing results of primary and secondary analyses from randomized controlled clinical trials and observational studies that have evaluated the use of buprenorphine to treat adolescents and young adults with OUD. Based on results from these studies, we encourage the conceptualization of OUD among youth as a chronic medical condition requiring a long-term management strategy. This includes treatment with buprenorphine in conjunction with medication-prescribing protocols that do not necessarily require daily clinic attendance for observed medication adherence. However, more study of treatment delivery models, addressing such issues as medication adherence and intensity requirements, is needed to determine practices that optimize outcomes for youth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.